Figure 4.

SPECT/CT imaging of mice with SK-RC-52 tumors.

SPECT/CT analysis was performed to visualize the biodistribution and the intra-tumoral distribution of the radiolabeled antibody. Sixteen mice bearing SK-RC-52 were treated with sunitinib for 7 days and injected with ¹¹¹In-Girentuximab with a specific activity of 22,5 MBq/5 μg, 3 days before start or 3 days after stop of treatment. Micro-SPECT images of mouse bearing SK-RC-52 tumor on right flank (arrow) at 7 d after injection of ¹¹¹In-girentuximab show that in addition to tumor uptake, minimal uptake in other organs was observed. More radiolabel was observed in the sunitinib treated tumors than in vehicle (A).This is in concordance with the biodistribution data. In all groups radiolabel was distributed throughout the tumor and no difference in radiolabel distribution was observed in the various treatment groups (B).